51 results about "Bone morphogenesis" patented technology

The present invention relates to a composition for preventing or treating metabolic diseases, which contains bone morphogenetic protein 10 (BMP10) as an active ingredient. It has been confirmed that BMP10-treated mouse embryonic mesenchymal cell line C3H10T1 / T2 cells promoted brown fat differentiation, and increased brown fat differentiation of stromal vascular fraction adipose stem cells isolated from subcutaneous adipose tissue. It has also been confirmed that BMP10-treated animal models of obesity induced weight loss, improved insulin resistance, and changes in blood lipid levels resulted. Therefore, the composition containing BMP10 as an active ingredient can be used as a preventive or therapeutic agent for metabolic diseases, including obesity, diabetes, and dyslipidemia.

The invention discloses a bone repair material as well as a preparation method and application thereof. The bone repair material is prepared from recombinant human collagen, recombinant human bone morphogenetic protein 2 and hydroxyapatite, wherein the ratio of the inorganic matter to the organic matter in the bone repair material is (64-66): (36-34). The bone repair material disclosed by the invention takes the recombinant human collagen as a core raw material, so that the components and the structure of the prepared material are ensured to be highly consistent with those of natural bone tissues; secondly, by adding the recombinant human bone morphogenetic protein 2, the osteogenic activity of the material is further enhanced. The finally obtained recombinant human collagen active bone repair material completely retains the triple helix structure of the recombinant human collagen, so that the recombinant human collagen active bone repair material has complete biological activity, and also has the outstanding advantages of good osteogenic activity, no disease and virus transmission risk and no immunogenicity.

The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being a cardiac Troponin, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), comparing the amounts of the biomarkers to references for said biomarkers and / or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and / or the calculation. The invention also relates to the use of a first biomarker being a cardiac Troponin and a second biomarker selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.

Methods of improving PD-1 based immunotherapy in a subject suffering from a solid cancer, comprising decreasing bone morphogenetic protein 1 (BMP1) levels or function in T cells or in a tumor microenvironment (TME) or extracellular matrix (ECM) of the solid cancer are provided. Methods of treating a solid cancer comprising administering a PD-1 based immunotherapy and decreasing BMP1 levels or function in T cells or a TME or ECM of the solid cancer are also provided. Antibody drug conjugates comprising an anti-PDl blocking antibody and a BMP1 inhibiting small molecule or antibody or antigen binding fragment thereof small molecule inhibitor and pharmaceutical compositions for use in the methods of the invention are also provided.

The application provides a DNA tetrahedron-based complex and a preparation method and application thereof, and belongs to the field of medicines. The application designs a functionalized DNA tetrahedron complex modified bioactive composite hydrogel scaffold containing BMP-2, combines the functionalized BMP-2 binding peptide with the tetrahedron framework structure with unique three-dimensional spatial structure and fine programmability through a chemical clicking mode, and further prepares the composite hydrogel scaffold by combining with methacrylated hyaluronic acid. The functionalized DNA tetrahedron complex realizes the performance of efficiently capturing BMP-2, and the composite hydrogel scaffold realizes the targeted capture of endogenous BMP-2 in the early stage of bone defect and stimulates the osteogenic differentiation of stem cells to promote in-situ osteogenesis, avoids a series of complications caused by the delivery of exogenous bone morphogenetic protein-2, and solves the problems of poor in-vivo stability, safety and high cost, and has a good application prospect.

A suture anchor includes an implanted portion configured to insert within an opening formed in bone of a patient and exposed portion configured to remain exposed. One or more sutures are laced through at least the implanted portion and possibly the exposed portion. Once tensioned, the suture causes the implanted portion to wedge within the opening and resist removal. The exposed portion may be placed over and / or around tissue and the suture may be passed through the tissue and knotted to secure the tissue to the suture anchor. The implanted portion may be infused with bone growth factors and the exposed portion may be infused with healing factors, such as Bone Morphogenic Protein-2 (BMP-2) and Platelet Rich Plasma (PRP).

The application provides a bone morphogenetic protein BMP-2 recombinant protein, and the amino acid sequence of the BMP-2 recombinant protein is shown as SEQ ID No. 1. The coding gene, the expression plasmid, the prokaryotic expression vector and the prokaryotic expression method are also disclosed. The prokaryotic expression system is adopted, and a solubilization tag is creatively introduced, so that the inclusion body expression is converted into soluble expression. The BMP-2 is expressed in the form of inclusion body in the prokaryotic system, the protein is converted into soluble expression by adding the solubilization tag, the difficulty of protein separation and purification is reduced, the purification cycle is shortened, and the purification efficiency is improved.

A composition comprising primed extracellular vesicles and a biologically or pharmaceutically acceptable carrier, wherein the primed extracellular vesicles comprise an upregulated miRNA, and a fold change of the upregulated miRNA of the primed extracellular vesicles compared to miRNA of naturally occurring extracellular vesicles is greater than 1. A method for preventing, treating, or ameliorating a bone defect or a dental defect comprising administering the composition to a subject in need thereof. A method for producing the composition, comprising: cultivating a stem cell in a culture medium containing a Polygonum multiflorum Thunb extract and at least one selected from the group consisting of baicalin and bone morphogenetic protein 6 to obtain a cell culture.

The present invention provides antibodies that bind to BMP6 and methods of use. According to certain embodiments of the present invention, the antibodies are fully human antibodies that bind to BMP6. The antibodies of the present invention are useful for inhibiting the binding of BMP6 to hemojuvelin receptors, thereby downregulating the transcription and expression of hepcidin, thereby providing a means for preventing or treating iron deficiency anemia or iron deficiency-related disorders. In some embodiments, the antibodies of the present invention are used to treat at least one symptom or complication of iron deficiency anemia or iron deficiency-related disorders.

The invention discloses siRNA (small interfering Ribonucleic Acid) of targeted bone morphogenetic protein 2, modified siRNA and application of the siRNA. According to the invention, siRNA drug design is carried out by taking the BMP2 gene as a target gene to obtain a series of siRNAs, siRNAs capable of effectively silencing the mRNA expression level of the BMP2 gene are screened from the siRNAs, and part of siRNA sequences can even silence the mRNA level of the BMP2 gene to about 25%. The siRNA sequence is further modified, wherein phosphorylation or phosphorylation analogue modification, skeleton modification, sugar ring modification and basic group modification are carried out on the 5'terminal of the sequence, or cholesterol molecule modification is carried out on the end group of the siRNA. The siRNA sequence is further subjected to cholesterol modification to obtain a human-mouse homologous sequence of the targeted BMP2 gene, and the in-vivo silencing activity of the BMP2 target spot is further researched in a mouse experimental model subsequently.

The invention provides a method of producing a population of CD34+ hematopoietic precursor cells. The CD34+ hematopoietic precursor cells are used in methods of producing natural killer (NK), methods of inducing NK cell differentiation from pluripotent stem cells (PSCs), and methods of generating terminally differentiated hematopoietic cells from PSCs. The differentiation of immune cells such as NK cells from PSCs includes the use of a hemogenic endothelium induction cocktail that includes a WNT signaling pathway activator, a bone morphogenetic protein and / or a vascular endothelial growth factor. Also provided is a method of producing hematopoietic stem cells from pluripotent stem cells.

The present invention provides antibodies that bind to BMP6, and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to BMP6. The antibodies of the invention are useful for inhibiting binding of BMP6 to the hemojuvelin receptor, thereby down-regulating transcription and expression of hepcidin, thus providing a means of preventing or treating an iron-deficiency anemia or an iron-deficiency related disorder. In some embodiments, the antibodies of the present invention are used in treating at least one symptom or complication of an iron-deficiency anemia or an iron-deficiency related disorder.

The present invention relates to the field of diagnostics. Specifically, it relates to a method for assessing congestion in a subject, the method comprising the steps of determining the amount of a BMP10-type peptide (Bone Morphogenetic Protein Type 10 peptide) in a sample of the subject, and comparing the amount of the BMP10-type peptide to a reference for the BMP10-type peptide, thereby assessing congestion. The invention also considers a method for distinguishing precapillary pulmonary hypertension from postcapillary pulmonary hypertension. Further, the present invention relates to a computer-implemented method of the aforementioned method as well as to a device and a kit for implementing said method. The present invention also generally relates to the use of a BMP10-type peptide or a detection agent therefor in a sample of a subject for assessing hyperemia, or the use of a BMP10-type peptide or a detection agent therefor in a sample of a subject for differentiating pre-capillary pulmonary hypertension from post-capillary pulmonary hypertension.

This invention discloses a composition for the differentiation of mesenchymal stem cells (ADSCs) into keratinocytes and its application. The composition comprises: a Wnt signaling pathway activator, a TGF-β signaling pathway inhibitor, a bone morphogenetic protein pathway activator, and at least one of retinoic acid and a retinoic acid agonist. The small molecule composition provided by this invention is meticulously designed to gradually guide the fate transition of ADSCs by mimicking key signaling events during embryonic development. This strategy is not a simple compound screening, but a rational design based on a deep understanding of developmental biology, achieving precise regulation of cell lineages in vitro by reproducing the natural developmental process. The composition of this invention is not a simple superposition of components, but rather achieves cell fate transition by precisely regulating the balance of signaling pathway networks.

The disclosure relates to compositions and methods of treating, improving, and accelerating the healing of large segmental bone defects in a subject. The method comprises administering to a patient in need of treatment an effective amount of whole blood, sodium citrate, ecarin and BMP-2.

The present application relates generally to the field of bone morphogenetic protein (BMP) antagonists (soluble ALK6 fusion proteins), compositions thereof, and methods for treating degenerative and / or demyelinating diseases of the nervous system.

To provide a defined culture medium for isolating stratified epithelial stem cells and stably maintaining the epigenetics of the stratified epithelial stem cells during multiple passages, and to provide clonal stratified epithelial stem cells isolated using the defined culture medium.SOLUTION: And a defined culture medium comprising each of ROCK (Rho kinase) inhibitors, mitogenic growth factors, insulin or IGF, TrkA inhibitors, and Oct4 activators, and comprising at least one of VEGF inhibitors, tyrosine kinase inhibitors, and / or FGF10 or FGF10 agonists, and optionally further comprising TGF β signaling pathway inhibitors and / or bone morphogenetic proteins (BMP) antagonists, wherein the defined culture medium supports epigenetically stable growth and proliferation of stem cells of stratified epithelial tissue origin in culture.SELECTED DRAWING: Figure 1

The application discloses a bone cement material, a preparation method and application thereof. The bone cement material is prepared from a bone cement raw material which is composed of polyethylene glycol (PEG) and calcium phosphate (CPC) and doped with bone morphogenetic protein-2 (BMP-2) under the action of a crosslinking agent. The bone cement material has the properties of slow and stable release, high osteogenic activity and the like under the condition of adding a small amount of BMP-2.

The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from said subject, and comparing said amount of BMP10 to a reference amount, whereby atrial fibrillation is assessed. Furthermore, the present invention relates to a method for diagnosing heart failure based on the determination of BMP10 in a sample from a subject. In addition, the present invention relates to a method for predicting the risk of a subject to be hospitalized due to heart failure based on the determination of BMP10-type peptides in a sample from a subject. The present invention further relates to antibodies binding to one or more BMP10-type peptides, such as NT-proBMP10.

Provided are unique affibodies specific for bone morphogenetic protein 2 (BMP-2), vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), platelet-derived growth factor (PDGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), inteleukin-4 (IL-4), and glial derived neurotrophic factor (GDNF), and well as hydrogels that include the affibodies and the corresponding protein. Also provided are methods of using the hydrogels, for example to treat bone injury, wounds, and neuron injury. In some examples, the hydrogel includes at least two different affibodies specific for the same protein, but have different disassociation constants (KD). Also provided are methods of using the affibodies to treat a disease, wound, injury, or cancer.

The invention belongs to the technical field of nano drug delivery systems, and particularly relates to a bone morphogenetic protein loaded nano drug delivery system and application in postoperative healing, and the bone morphogenetic protein loaded nano drug delivery system comprises a composite carrier, a targeted modification layer and loaded bone morphogenetic protein; the composite carrier is formed by compounding an inorganic nano material and a biodegradable polymer, the targeted modification layer is a bone injury part specific recognition molecule, and the nano drug-loading system has an intelligent release mechanism responding to a bone healing microenvironment and can be applied to orthopedic postoperative healing.

Provided are dual-affinity fusion proteins including an affibody domain specific for a therapeutic protein, and including a localization domain specific for a structural bone component. The therapeutic protein can include bone morphogenetic protein 2 (BMP-2), vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), platelet-derived growth factor (PDGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), or glial derived neurotrophic factor (GDNF). Also provided are compositions that include the dual-affinity fusion proteins, affibodies and the corresponding therapeutic proteins, and / or a medical material used to treat a wound, or a bone or cartilage injury or disease. Also provided are methods of using the compositions, for example to treat bone injuries, bone diseases, cartilage injuries, cartilage diseases, and wounds. In some examples, the composition includes at least two different dual-affinity fusion proteins specific for the same therapeutic protein, but have different disassociation constants (KD).

A bone graft material includes a shielding film configured to cover an upper surface of a bone defect and separate the bone defect from an external environment and impregnated with a bone morphogenetic protein-2 (BMP-2) solution, and a filler that contacts a lower surface of the shielding film and is configured to fill the bone defect. The bone graft material is designed such that, by impregnating the BMP-2 solution into the shield film so as to form a bone cover of the bone defect, and the filler at the bottom of the shield film can sufficiently form bone in the cover.

The application discloses a plastic bone repair composite scaffold loaded with bone morphogenetic protein-2 and a preparation method thereof, and belongs to the technical field of biological repair materials. The preparation method comprises the following steps: mixing biological ceramic powder, modified starch and deionized water to obtain ceramic slurry through wet grinding, printing the ceramic slurry to obtain a biological ceramic scaffold blank, crushing the biological ceramic scaffold blank after sintering treatment to obtain biological ceramic particles; mixing the biological ceramic particles and a collagen fiber slurry, defoaming and then freeze-drying to obtain a ceramic collagen composite scaffold; placing the ceramic collagen composite scaffold into a crosslinking mixed solution for crosslinking, and then sequentially performing water washing, freeze-drying and sterilization to obtain a bone repair porous scaffold; and adding a CBD-rhBMP-2 solution dropwise to the bone repair porous scaffold to obtain the bone repair composite scaffold. The bone repair composite scaffold prepared by the method has good plastic stability and compressive strength, and has good osteogenic activity, and has practical use value.

The application discloses an active bone defect repairing material and a preparation method thereof. The bone defect repairing material is prepared by compounding collagen extracted from an animal source, calcined bone matrix and bone morphogenetic protein composite microspheres, and is formed by light curing 3D printing technology. The application is based on the bionic angle, and collagen is used as a framework material, the calcined bone matrix with low immunogenicity is used as a hard material to enhance the mechanical support, and the bone morphogenetic protein composite microspheres are used as a synergistic material to long-effectively guide the undifferentiated mesenchymal stem cells to develop in a specific direction. After the active bone defect repairing material is implanted into a bone defect part, a microenvironment beneficial to cell adhesion and proliferation is provided for cells, and the slow release of the bone morphogenetic protein can long-effectively act on the bone defect part, effectively promotes the differentiation and maturation process of osteoblasts, and promotes the bone repair of the bone defect part.

This document provides methods and materials involved in promoting bone growth. For example, this document provides vectors designed to express (a) a nucleotide sequence encoding a bone morphogenetic protein 2 (BMP2) polypeptide and / or (b) a nucleotide sequence encoding an interleukin-1 receptor antagonist (IL-1Ra) polypeptide for promoting bone growth. In some cases, one or more vectors provided herein can be administered to a mammal (e.g., a human) having a disease, disorder, or condition associated with bone loss to treat the mammal. For example, a population of a single vector provided herein can be used to increase expression of a BMP2 polypeptide and an IL-1Ra polypeptide by cells within a mammal (e.g., a human) having a disease, disorder, or condition associated with bone loss to promote bone growth within the mammal.

Methods to promote thymic regeneration are described. The methods can inhibit nucleotide-binding oligomerization domain-containing protein 2 (NOD2), Rho GTPases, and / or microRNA 29c (miR29c). These inhibition methods can promote regenerative molecules, such as interleukin (IL)-22, IL-23, and / or bone morphogenetic protein 4 (BMP4). Promoting thymic regeneration can be beneficial in patients due to age, infection, or cancer therapies.

To provide ventral hindgut organoids for producing bladder organoids with a layered structure of bladder epithelial cell types similar to those in the bladder.SOLUTION: One aspect of the present invention provides a method for producing ventral hindgut organoids, comprising culturing pluripotent stem cells using induction medium A containing activin A and a GSK3β inhibitor to induce differentiation into definitive endoderm cells, and culturing the definitive endoderm cells using induction medium B that contains a fibroblast growth factor and a GSK3β inhibitor and further may contain a bone morphogenetic protein, and then culturing the cells in induction medium B that contains a fibroblast growth factor and a GSK3β inhibitor and further may contain a bone morphogenetic protein, in the presence of an extracellular matrix, to form ventral hindgut organoids.SELECTED DRAWING: None